Carbidopa (Lodosyn)

An inhibitor of DOPA DECARBOXYLASE that prevents conversion of LEVODOPA to dopamine. It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA. It has no anti-parkinson activity by itself.

Also Known As:

Networked: 1020 relevant articles (108 outcomes, 167 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Nyholm, Dag: 25 articles (06/2022 - 10/2006)
2.	Antonini, Angelo: 24 articles (08/2021 - 07/2009)
3.	Odin, Per: 20 articles (06/2022 - 07/2009)
4.	Chatamra, Krai: 18 articles (07/2018 - 03/2013)
5.	Lopiano, Leonardo: 17 articles (09/2022 - 03/2011)
6.	Müller, Thomas: 17 articles (01/2022 - 03/2006)
7.	Robieson, Weining Z: 16 articles (10/2021 - 02/2014)
8.	Bergmann, Lars: 15 articles (01/2022 - 03/2015)
9.	Poewe, Werner: 15 articles (11/2021 - 07/2010)
10.	Chaudhuri, K Ray: 13 articles (01/2022 - 07/2009)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2004 - "The efficacy of domestic drug tremonorm (levadopa-carbidopa) for Parkinson's disease (PD) treatment was studied. " 01/01/1973 - "A double-blind controlled study of MK-486 in Parkinson's disease." 01/01/2022 - "We further show that carbidopa, an FDA-approved drug for Parkinson's disease as well as an AhR agonist, inhibits IDO1 expression in PDAC cells. " 01/01/2020 - "PK and safety profiles of single dose CVT-301, administered with oral carbidopa (CD) and oral CD/LD, were examined in patients with Parkinson's disease in the fed state. " 01/01/2019 - "We present a 48-year-old woman with Parkinson's disease in whom carbidopa was added to Mucuna pruriens, resulting in marked motor improvement (documented on video and using MDS-UPDRS motor scores). "
2.	Dyskinesias (Dyskinesia) 11/01/2016 - "Several levodopa/carbidopa intestinal gel (LCIG) studies showed a significant reduction of OFF time and a significant increase of ON time, as well as a reduction of dyskinesia, and improvement of non-motor symptoms and quality of life. " 12/01/2022 - "Compared with levodopa-carbidopa, foslevodopa-foscarbidopa showed a significantly greater increase in on time without troublesome dyskinesia (model-based mean [SE] 2·72 [0·52] vs 0·97 [0·50] h; difference 1·75 h, 95% CI 0·46 to 3·05; p=0·0083) and a significantly greater reduction in off time (-2·75 [0·50] vs -0·96 [0·49] h; difference -1·79 h, -3·03 to -0·54; p=0·0054). " 12/01/1996 - "Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation." 01/01/2010 - "Administration of aplindore (1.0 mg/kg p.o.) in combination with L-dopa (2.5 mg/kg plus carbidopa 12.5 mg/kg p.o.) did not inhibit the reversal of motor deficits but improved motor disability and increased both locomotor activity and dyskinesia expression equivalent to that produced by L-dopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o.). " 03/01/2005 - "Administration of L-dopa (12.5 mg/kg p.o.) plus carbidopa twice daily produced fluctuating improvement in motor behavior coupled with dyskinesia. "
3.	Parkinsonian Disorders (Parkinsonism) 10/01/1978 - "Need for uncombined carbidopa to treat parkinsonism." 01/01/1997 - "Low-dose pergolide together with L-carbidopa is effective in the treatment of parkinsonism without side effects, even in advanced stages of the disease. " 02/01/1977 - "[Effect of MK-486 alone on Parkinsonism; studies on the clinical symptoms and catecholamine concentrations in the blood, urine and cerebrospinal fluid]." 01/01/2022 - "Here we report three cases of post COVID parkinsonism occurring in older adults, age 60 years and above, and their response to levodopa-carbidopa." 11/17/2018 - "For the management of the drug-induced parkinsonism, levodopa/carbidopa was prescribed and the symptoms related to parkinsonism resolved within a week. "
4.	Amblyopia (Lazy Eye) 07/01/1995 - "The present study confirms previous findings of improvement in visual function in amblyopia after levodopa/carbidopa administration. " 03/01/2009 - "Levodopa/carbidopa improves visual acuity in patients with amblyopia and maintains improved visual acuity, especially in patients younger than 8 years." 09/01/1992 - "The results are discussed in the context of developing a therapeutic trial of levodopa/carbidopa for childhood amblyopia." 11/01/2023 - "To review the published literature on the use of levodopa/carbidopa to augment the treatment of amblyopia. " 11/01/2023 - "Levodopa/Carbidopa to Augment the Treatment of Amblyopia: A Report by the American Academy of Ophthalmology."
5.	Myoclonus (Nocturnal Myoclonus) 12/01/1982 - "This rank order of potency differed from that observed for the order of potency of these drugs in inhibiting the myoclonus induced by L-5-hydroxytryptophan (5HTP) plus carbidopa in guinea-pigs (Luscombe, Jenner and Marsden, Neuropharmacology, 1981), perhaps indicating involvement of pharmacologically distinct indoleamine receptors. " 06/01/1980 - "Six patients with myoclonus of varying cause were treated with L-5-hydroxytryptophan (L-5-HTP) and carbidopa. " 06/01/1980 - "Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations." 12/01/1976 - "L-5-hydroxytryptophan plus carbidopa was administered to eight patients with this disorder or other syndromes in which myoclonus is prominent. " 01/01/1976 - "Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa."

Related Drugs and Biologics

1.	Levodopa (L Dopa)
2.	levodopa drug combination carbidopa (Nakom)
3.	5-Hydroxytryptophan (5 Hydroxytryptophan)
4.	entacapone (Comtan)
5.	Benserazide
6.	Dopamine (Intropin)
7.	Prodrugs
8.	Pergolide (Permax)
9.	Carboxy-Lyases
10.	Clonazepam (Rivotril)

Related Therapies and Procedures

1.	Therapeutics
2.	Deep Brain Stimulation
3.	Subcutaneous Infusions
4.	Drug Tapering
5.	Renal Dialysis (Hemodialysis)